<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00680485</url>
  </required_header>
  <id_info>
    <org_study_id>OPS108221</org_study_id>
    <nct_id>NCT00680485</nct_id>
  </id_info>
  <brief_title>Evaluation of the Safety, Tolerability and Pharmacokinetics of Repeat Oral Doses of GSK580416</brief_title>
  <official_title>A Three Part Study in Healthy Adult Subjects to Evaluate the Safety, Tolerability and Pharmacokinetics of Repeat Escalating Oral Doses of GSK580416; the Safety, Tolerability, and Pharmacokinetics of GSK580416 Following a Loading Dose Regimen; and the Effect of Ketoconazole on the Pharmacokinetics of GSK580416</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate the safety, tolerability and exposure of repeat escalating oral
      doses, a loading dose/maintenance dose regimen of GSK580416 and when co administered with
      ketoconazole, a PGP/CYP3A4 inhibitor.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A three part study in healthy adult subjects to evaluate the safety, tolerability and
      pharmacokinetics of repeat escalating oral doses of GSK580416; the safety, tolerability, and
      pharmacokinetics of GSK580416 following a loading dose regimen; and the effect of
      ketoconazole on the pharmacokinetics of GSK580416
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <start_date>June 2007</start_date>
  <completion_date type="Actual">October 2007</completion_date>
  <primary_completion_date type="Actual">October 2007</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety and tolerability of GSK580416 doses determined from clinical safety and tolerability data from all adverse event reporting, 12-lead ECGs, vital signs, nursing/physician observation, and safety laboratory tests</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of GSK580416 as determined by AUC, Cmax, tmax, half-life, and Ct.</measure>
  </secondary_outcome>
  <enrollment>96</enrollment>
  <condition>Bacterial Infection</condition>
  <condition>Infections, Bacterial</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GSK580416 oral tablets (250 mg) Ketoconazole oral tablets (200 mg)</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy adults (as determined by medical evaluation including history, physical exam,
             vital signs, laboratory tests, and cardiac monitoring)

          -  Aged 18-60yrs, with BMI of 19-31kg/m2.

          -  Females must be of non-childbearing potential.

          -  QTc &lt; 450 msec at screening.

          -  Subjects must be able to give consent and comply with restrictions of study.

        Exclusion Criteria:

          -  Clinically significant CNS, cardiac, pulmonary, metabolic, renal, hepatic or GI
             condition or history that may place the subject at an unacceptable risk or may
             interfere with absorption, distribution, metabolism, or excretion of drug.

          -  Positive urine drug screen.

          -  Positive urine test for alcohol.

          -  Positive HIV or Hep B and/or C assay.

          -  History of regular tobacco use within 3 monts prior to screening or cotinine levels
             indicative of smoking at screening.

          -  History of regular alcohol consumption (14 units/week for women and 21 units/week for
             men).

          -  History of drug abuse or dependence within 12 months of study.

          -  Participation in another drug trial within 30 days of first dose.

          -  Exposure to more than 4 new chemical entities within 12 months of first dose.

          -  Use of prescription and non-prescription drugs including vitamins, dietary
             supplements, herbals within 7 days of first dose or St. John's Wort within 28 days of
             the first dose.

          -  Consumption of red wine, Seville oranges, grapefruit, or grapefruit juices within 14
             days of first dose.

          -  Donation of blood in excess of 500 mL within 56 days of dosing. No blood donation is
             allowed 30 days prior to study participation.

          -  A positive immunochemical fecal occult blood test at screening.

          -  History of sensitivity to any of the study medications.

          -  History of sensitivity to heparin or heparin-induced thrombocytopenia.

          -  History of orthostatic hypotension or orthostatic hypotension at screening.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>64 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Adelaide</city>
        <state>South Australia</state>
        <zip>5000</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
  </location_countries>
  <verification_date>January 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 14, 2008</study_first_submitted>
  <study_first_submitted_qc>May 16, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 20, 2008</study_first_posted>
  <last_update_submitted>January 19, 2017</last_update_submitted>
  <last_update_submitted_qc>January 19, 2017</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 20, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>GSK580416</keyword>
  <keyword>ketoconazole interaction</keyword>
  <keyword>pleuromutilin</keyword>
  <keyword>oral dose</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Bacterial Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ketoconazole</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

